New Wave Wealth Advisors LLC Acquires 349 Shares of Zimmer Biomet Holdings, Inc. $ZBH

New Wave Wealth Advisors LLC increased its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 16.8% during the second quarter, Holdings Channel.com reports. The fund owned 2,431 shares of the medical equipment provider’s stock after purchasing an additional 349 shares during the quarter. New Wave Wealth Advisors LLC’s holdings in Zimmer Biomet were worth $222,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. Janney Montgomery Scott LLC increased its stake in shares of Zimmer Biomet by 0.5% in the 1st quarter. Janney Montgomery Scott LLC now owns 25,647 shares of the medical equipment provider’s stock valued at $2,903,000 after acquiring an additional 118 shares in the last quarter. Curbstone Financial Management Corp increased its stake in Zimmer Biomet by 3.4% during the 1st quarter. Curbstone Financial Management Corp now owns 4,266 shares of the medical equipment provider’s stock valued at $483,000 after purchasing an additional 140 shares in the last quarter. Brooklyn Investment Group increased its stake in Zimmer Biomet by 45.9% during the 1st quarter. Brooklyn Investment Group now owns 461 shares of the medical equipment provider’s stock valued at $52,000 after purchasing an additional 145 shares in the last quarter. Roberts Wealth Advisors LLC increased its stake in Zimmer Biomet by 0.8% during the 1st quarter. Roberts Wealth Advisors LLC now owns 18,497 shares of the medical equipment provider’s stock valued at $2,093,000 after purchasing an additional 152 shares in the last quarter. Finally, Wesbanco Bank Inc. increased its stake in Zimmer Biomet by 0.8% during the 1st quarter. Wesbanco Bank Inc. now owns 20,012 shares of the medical equipment provider’s stock valued at $2,265,000 after purchasing an additional 163 shares in the last quarter. 88.89% of the stock is owned by institutional investors.

Zimmer Biomet Stock Performance

NYSE ZBH opened at $98.86 on Thursday. Zimmer Biomet Holdings, Inc. has a 1 year low of $89.22 and a 1 year high of $114.72. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.87 and a quick ratio of 0.96. The firm has a market cap of $19.58 billion, a price-to-earnings ratio of 24.05, a PEG ratio of 2.27 and a beta of 0.67. The company has a fifty day moving average price of $100.76 and a 200-day moving average price of $98.98.

Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.98 by $0.09. Zimmer Biomet had a net margin of 10.51% and a return on equity of 12.76%. The firm had revenue of $2.08 billion during the quarter, compared to analyst estimates of $2.06 billion. During the same quarter in the prior year, the business posted $2.01 EPS. The business’s revenue was up 7.0% compared to the same quarter last year. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. As a group, equities research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date of this dividend is Tuesday, September 30th. Zimmer Biomet’s payout ratio is 23.36%.

Wall Street Analyst Weigh In

A number of brokerages have commented on ZBH. Rothschild Redb upgraded shares of Zimmer Biomet to a “strong-buy” rating in a research note on Thursday, September 18th. Evercore ISI decreased their price target on shares of Zimmer Biomet from $102.00 to $96.00 and set an “in-line” rating for the company in a research note on Tuesday, July 8th. Redburn Partners set a $130.00 price target on shares of Zimmer Biomet in a research note on Thursday, September 18th. Royal Bank Of Canada boosted their price target on shares of Zimmer Biomet from $112.00 to $115.00 and gave the company an “outperform” rating in a research note on Friday, August 8th. Finally, Stifel Nicolaus upped their target price on shares of Zimmer Biomet from $115.00 to $118.00 and gave the stock a “buy” rating in a research note on Friday, September 19th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, seven have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $113.16.

Insider Buying and Selling at Zimmer Biomet

In related news, SVP Lori Winkler sold 1,500 shares of the business’s stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $104.15, for a total value of $156,225.00. Following the transaction, the senior vice president directly owned 6,833 shares of the company’s stock, valued at approximately $711,656.95. The trade was a 18.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 1.39% of the company’s stock.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.